ReviewDrug design, development and therapy2019
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Tugrul Elverdi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it